Reports Q4 revenue $65.65B, consensus $63.18B. “While higher medical costs in our stop loss product impacted fourth quarter earnings, we are ...

Sees FY25 adjusted revenue at least $252,000. Sees FY25 capital expenditures $1.4B. Sees FY25 effective tax rate 19%. The company said, “The ...

It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

After a dip in the wake of the release of UnitedHealth Group's Q4 2024 earnings figures, shares in the company and other ...

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...